Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ICLR
stocks logo

ICLR

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.98B
-6.81%
3.295
-12.13%
1.97B
-2.83%
3.480
+3.88%
1.99B
-2.39%
3.634
+5.95%
Estimates Revision
The market is revising Downward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by -4.61% over the past three months. During the same period, the stock price has changed by -20.58%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.48%
In Past 3 Month
Stock Price
Go Down
down Image
-20.58%
In Past 3 Month
14 Analyst Rating
up Image0
Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 171.25 USD with a low forecast of 144.00 USD and a high forecast of 200.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
6 Hold
0 Sell
Moderate Buy
up Image0
Current: 146.480
sliders
Low
144.00
Averages
171.25
High
200.00
up Image0
Current: 146.480
sliders
Low
144.00
Averages
171.25
High
200.00
Redburn Atlantic
Neutral
downgrade
$232 -> $144
2025-05-23
Reason
Redburn Atlantic
Price Target
$232 -> $144
2025-05-23
downgrade
Neutral
Reason
Redburn Atlantic lowered the firm's price target on Icon to $144 from $232 and keeps a Neutral rating on the shares. Based on the lingering cancellations from last year, as well as the slowdown in demand from policy uncertainty, the firm does not expect bookings to stabilize for Icon until mid-2026.
Mizuho
Outperform -> NULL
downgrade
$200 -> $173
2025-05-15
Reason
Mizuho
Price Target
$200 -> $173
2025-05-15
downgrade
Outperform -> NULL
Reason
Mizuho lowered the firm's price target on Icon to $173 from $200 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q1 report.
TD Cowen
Charles Rhyee
Strong Buy
to
Hold
Downgrades
$254 → $157
2025-04-14
Reason
TD Cowen
Charles Rhyee
Price Target
$254 → $157
2025-04-14
Downgrades
Strong Buy
to
Hold
Reason
Truist Securities
Jailendra Singh
Strong Buy
Maintains
$262 → $208
2025-04-10
Reason
Truist Securities
Jailendra Singh
Price Target
$262 → $208
2025-04-10
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Icon to $208 from $262 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results for Contract Research Organizations, or CROs. The firm is lowering its estimates and price targets for to reflect recent trends and macro uncertainty. Truist states it had previously believed that large pharma market was already halfway through with respect to portfolio reprioritization, but given the funding trends of the past two months and the uncertain pharma industry environment in general, its baseline assumption now sees biotech recovery being pushed out to at least the second half of 2025 and the large pharma market recovery to the first half of 2026, the analyst tells investors in a research note.
Barclays
Luke Sergott
Buy
to
Hold
Downgrades
$240 → $165
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$240 → $165
2025-04-10
Downgrades
Buy
to
Hold
Reason
Mizuho
Ann Hynes
Buy
Maintains
$238 → $200
2025-04-09
Reason
Mizuho
Ann Hynes
Price Target
$238 → $200
2025-04-09
Maintains
Buy
Reason
Mizuho analyst Ann Hynes lowered the firm's price target on Icon to $200 from $238 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.
See All Ratings

Valuation Metrics

The current forward P/E ratio for ICON PLC (ICLR.O) is 10.30, compared to its 5-year average forward P/E of 19.41. For a more detailed relative valuation and DCF analysis to assess ICON PLC 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PE
19.41
Current PE
10.30
Overvalued PE
23.34
Undervalued PE
15.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
14.27
Current EV/EBITDA
8.88
Overvalued EV/EBITDA
17.12
Undervalued EV/EBITDA
11.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
2.45
Current PS
1.39
Overvalued PS
2.98
Undervalued PS
1.93

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

ICLR News & Events

Events Timeline

(ET)
2025-04-30
16:28:52
Icon now sees FY adjusted EPS $12.75-$14.25, consensus $13.62
select
2025-04-30
16:28:00
Icon reports Q1 adjusted EPS $3.19, consensus $3.10
select
2025-03-04 (ET)
2025-03-04
09:07:17
Icon adopting Mural Health's participant management and payments platform
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
06-02PRnewswire
ICLR Shareholders Have the Right to Lead the ICON Public Limited Company Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ICLR

  • Class Action Lawsuit Against ICON: The DJS Law Group is reminding investors of a class action lawsuit against ICON Public Limited Company for alleged violations of federal securities laws, specifically regarding misleading statements about the company's business losses during a market downturn.

  • Investor Participation Encouraged: Shareholders who purchased ICON's securities between July 27, 2023, and October 23, 2024, are urged to contact the law firm before June 2, 2025, to participate in the lawsuit if they suffered financial losses.

Preview
3.5
05-20Newsfilter
ICON releases its ICON Cares 2024 Report

  • ICON Cares 2024 Report Highlights: ICON plc has released its 2024 report showcasing advancements in environmental, social, and governance (ESG) goals, achieving a score of 72/100 from EcoVadis and being recognized by TIME magazine as one of the World's Best Companies in Sustainable Growth for 2025. The company supported over 1,270 clinical studies and emphasized improving public health and access to clinical trials.

  • Environmental Initiatives and Innovations: ICON has made significant strides in reducing its environmental footprint, including a 70.06% reduction in Scope 1 & 2 greenhouse gas emissions and sourcing 84.67% of its electricity from renewable sources. Additionally, the company is leveraging artificial intelligence and technology to enhance clinical trial efficiency and patient access.

Preview
9.0
05-07Newsfilter
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

  • Survey Findings on Multi-Indication R&D: A survey by ICON plc reveals that 83% of biotech and pharma professionals are pursuing multi-indication approaches for obesity-related research, but many underestimate the complexities involved, particularly in trial design and data collection.

  • Potential Benefits and New Initiatives: The respondents believe that multi-indication R&D could lower healthcare costs and enhance patient options. ICON has launched a new Centre for Obesity to support this research with a robust infrastructure and access to a large pool of pre-screened patients.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ICON PLC (ICLR) stock price today?

The current price of ICLR is 146.48 USD — it has increased 2.02 % in the last trading day.

arrow icon

What is ICON PLC (ICLR)'s business?

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

arrow icon

What is the price predicton of ICLR Stock?

Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 171.25 USD with a low forecast of 144.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ICON PLC (ICLR)'s revenue for the last quarter?

ICON PLC revenue for the last quarter amounts to 2.00B USD, decreased -4.26 % YoY.

arrow icon

What is ICON PLC (ICLR)'s earnings per share (EPS) for the last quarter?

ICON PLC. EPS for the last quarter amounts to 1.90 USD, decreased -15.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for ICON PLC (ICLR)'s fundamentals?

The market is revising Downward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by -4.61% over the past three months. During the same period, the stock price has changed by -20.58%.
arrow icon

How many employees does ICON PLC (ICLR). have?

ICON PLC (ICLR) has 41900 emplpoyees as of June 23 2025.

arrow icon

What is ICON PLC (ICLR) market cap?

Today ICLR has the market capitalization of 11.64B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free